Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 14/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4110715 | 0.81 | EPHX2 (0.68) | CXCR3TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4981277 | 0.77 | EPHX2 (0.47) | CYP1A2CYP2C19EPHX2 | |
| SCHEMBL6158181 | 0.76 | SIGMAR1 (0.53) | EPHX2SIGMAR1HSD11B1 | |
| SCHEMBL23921328 | 0.75 | CXCR3 (0.39) | CXCR3TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6154505 | 0.73 | EPHX2 (0.58) | EPHX2SIGMAR1HSD11B1EPHX1 | |
| SCHEMBL8996650 | 0.72 | EPHX2 (0.68) | EPHX2ARKCNH2SIGMAR1 | |
| SCHEMBL9315978 | 0.71 | EPHX1 (0.67) | CYP1A2CYP3A4CYP2C19EPHX2EPHX1 | |
| SCHEMBL6154998 | 0.70 | SIGMAR1 (0.53) | EPHX2SIGMAR1HSD11B1 | |
| SCHEMBL6156772 | 0.69 | EPHX2 (0.47) | CYP1A2CYP3A4CYP2D6CYP2C19EPHX2 | |
| SCHEMBL1804522 | 0.68 | CXCR3 (0.50) | CXCR3TP53CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125762-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | UNIV DREXEL (US) | 2026-05-07 | — | — | US | claimed |
| US-20240254561-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | THOMAS JEFFERSON UNIVERSITY | 2024-08-01 | — | — | US | claimed |
| US-20200087730-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | UNIV DREXEL (US) | 2020-03-19 | — | — | US | claimed |
| WO-2018112122-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | DREXEL UNIVERSITY (US) | 2018-06-21 | — | — | WO | claimed |
| WO-2010128309-A1 | COMBINATION THERAPY COMPRISING A TAXANE AND A SIGMA RECEPTOR LIGAND SAUCH AS RIMCAZOLE | MODERN BIOSCIENCES, PLC. (GB) | 2010-11-11 | — | — | WO | claimed |
| WO-2005079767-A2 | MEANS FOR MODULATION OF THE EFFECTS OF OPIOID-LIKE SUBSTANCES | Universitätsklinikum Münster (DE) | 2005-09-01 | — | — | WO | claimed |
| US-20040019060-A1 | Sigma receptor ligands and their medical uses | SPRUCE BARBARA ANN (GB) | 2004-01-29 | — | — | US | claimed |
| JP-2003528916-A | — | — | 2003-09-30 | — | — | JP | claimed |
| US-20030027801-A1 | Methods of treatment of eye trauma and disorders | WYETH | 2003-02-06 | — | — | US | claimed |
| EP-1267875-A1 | SIGMA RECEPTOR LIGANDS AND THEIR MEDICAL USES | Spruce, Barbara (GB) | 2003-01-02 | — | — | EP | claimed |
| US-6358696-B1 | ADMINISTERING THERAPEUTICALLY EFFECTIVE AMOUNT OF ONE OR MORE SUBSTITUTED GUANIDINES TO TREAT DECREASED BLOOD FLOW OR NUTRIENT SUPPLY TO RETINAL TISSUE OR OPTIC NERVE, OR RETINAL ISCHEMIA OR TRAUMA, OR OPTIC NERVE INJURY | WYETH | 2002-03-19 | — | — | US | claimed |
| WO-2001074359-A1 | SIGMA RECEPTOR LIGANDS AND THEIR MEDICAL USES | SPRUCE BARBARA (GB) | 2001-10-11 | — | — | WO | claimed |
| WO-1999002145-A1 | COMBINATION DRUG THERAPIES COMPRISING AMINOGLYCOSIDE ANTIBIOTICS AND N,N'-DISUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-01-21 | — | — | WO | claimed |
| US-20260125762-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | UNIV DREXEL (US) | 2026-05-07 | — | — | US | disclosed |
| US-12582619-B2 | Compounds, compositions, and methods for treating or ameliorating, or preventing viral infections | THOMAS JEFFERSON UNIVERSITY (US) | 2026-03-24 | — | — | US | disclosed |
| WO-2025031979-A1 | USE OF RIMCAZOLE TO TREAT CANCER | KYREXA LTD (GB) | 2025-02-13 | — | — | WO | disclosed |
| US-5312840-A | Substituted guanidines having high binding to the sigma receptor and the use thereof | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION (US) | 1994-05-17 | — | — | US | disclosed |
| EP-0532642-A4 | — | — | 1994-04-27 | — | — | EP | disclosed |
| EP-0532642-A1 | SUBSTITUTED GUANIDINES HAVING HIGH BINDING TO THE SIGMA RECEPTOR AND THE USE THEREOF | STATE OF OREGON, acting through OREGON STATE BOARD OF HIGHER EDUCATION, acting for OREGON HEALTH SC. UNIV. AND UNIV. OF OREGON (US) | 1993-03-24 | — | — | EP | disclosed |
| WO-1991018868-A1 | SUBSTITUTED GUANIDINES HAVING HIGH BINDING TO THE SIGMA RECEPTOR AND THE USE THEREOF | STATE OF OREGON, acting by and through the OREGON STATE BOARD OF HIGHER EDUCATION, acting for and onbehalf of the OREGON HEALTH SCIENCES UNIVERSITY (US) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019060-A1 | Sigma receptor ligands and their medical uses | TMEM97, SIGMAR1, GPR119 | CXCR3 212/4885TP53 3786/4885CYP1A2 451/4885 |
| US-20030027801-A1 | Methods of treatment of eye trauma and disorders | RBP4, ALDH1A2, RBP1 | CXCR3 2261/4885TP53 4568/4885CYP1A2 4444/4885 |
| US-20200087730-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | SIGMAR1, TMEM97, OPRK1 | CXCR3 2293/4885TP53 1713/4885CYP1A2 1297/4885 |
| US-20240254561-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | SIGMAR1, TMEM97, OPRK1 | CXCR3 2293/4885TP53 1713/4885CYP1A2 1297/4885 |
| US-12582619-B2 | Compounds, compositions, and methods for treating or ameliorating, or preventing viral infections | TMEM97, EIF2AK2, VCP | CXCR3 3320/4885TP53 2847/4885CYP1A2 2548/4885 |
| US-20260125762-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | IGF2BP3, RBM3, MORF4L1 | CXCR3 2713/4885TP53 1062/4885CYP1A2 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.